These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 3887443)

  • 41. [Long-term moditen-depot treatment of schizophrenic patients at a psychoneurology dispensary].
    Abramova LI; Gushanskiĭ EL
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1986; 86(3):419-24. PubMed ID: 3705854
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fluphenazine enanthate in the outpatient treatment of late paraphrenia.
    Raskind M; Alvarez C; Herlin S
    J Am Geriatr Soc; 1979 Oct; 27(10):459-63. PubMed ID: 469146
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Baclofen in the treatment of schizophrenia: a pilot study.
    Schöpf J; Hucker H
    Pharmakopsychiatr Neuropsychopharmakol; 1977 Mar; 10(2):89-91. PubMed ID: 360234
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of supersensitivity psychosis with antiepileptic drugs: report of a series of 43 cases.
    Chouinard G; Sultan S
    Psychopharmacol Bull; 1990; 26(3):337-41. PubMed ID: 2274634
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low dose medication strategies in the maintenance treatment of schizophrenia.
    Kane JM
    Schizophr Bull; 1983; 9(4):528-32. PubMed ID: 6140751
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients.
    Van Putten T; Aravagiri M; Marder SR; Wirshing WC; Mintz J; Chabert N
    Psychopharmacol Bull; 1991; 27(2):91-6. PubMed ID: 1924666
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences.
    Johnson DA; Pasterski G; Ludlow JM; Street K; Taylor RD
    Acta Psychiatr Scand; 1983 May; 67(5):339-52. PubMed ID: 6135298
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Auditory attention in process and reactive schizophrenia.
    Maloney MP; Sloane RB; Whipple K; Rzani J; Eaton EM
    Biol Psychiatry; 1976 Jun; 11(3):325-32. PubMed ID: 779856
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Adverse effects of long-term psychopharmacologic therapy on sexual functions].
    Pfeiffer W; Kockott G; Fischl B; Schleuning G
    Psychiatr Prax; 1991 May; 18(3):92-8. PubMed ID: 1886955
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fluphenazine treatment of DSM-III-R male schizophrenic patients among the Xhosa.
    Landmark J; Merskey H; Cernovsky ZZ
    Can J Psychiatry; 1994 May; 39(4):219-22. PubMed ID: 8044729
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fluphenazine decanoate in acute and maintenance therapy of schizophrenia.
    Altamura AC; Mauri MC; Guercetti G; Cazzullo CL
    Prog Neuropsychopharmacol Biol Psychiatry; 1987; 11(5):613-23. PubMed ID: 3122268
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Costs and benefits of two doses of fluphenazine.
    Marder SR; Van Putten T; Mintz J; McKenzie J; Lebell M; Faltico G; May PR
    Arch Gen Psychiatry; 1984 Nov; 41(11):1025-9. PubMed ID: 6437365
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Use of fluphenazine decanoate in psychiatric therapy. Multicenter study in 1095 patients preselected for long-acting neuroleptic treatment].
    Bogliolo C
    Minerva Psichiatr; 1986; 27(1):1-18. PubMed ID: 3713474
    [No Abstract]   [Full Text] [Related]  

  • 54. [Fluphenazine dihydrochloride--a multicenter trial on 660 patients (author's transl)].
    Pieschl D; Kulhanek F; Piergies A
    Arzneimittelforschung; 1978; 28(9):1503-4. PubMed ID: 383100
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlation of fluphenazine plasma levels versus clinical response in patients: a pilot study.
    Dudley J; Rauw G; Hawes EM; Keegan DL; Midha KK
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):791-5. PubMed ID: 6686710
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expressed emotion, fixed-dose fluphenazine decanoate maintenance, and relapse in recent-onset schizophrenia.
    Nuechterlein KH; Snyder KS; Dawson ME; Rappe S; Gitlin M; Fogelson D
    Psychopharmacol Bull; 1986; 22(3):633-9. PubMed ID: 3797570
    [No Abstract]   [Full Text] [Related]  

  • 57. Clinical symptomatology and drug compliance in schizophrenic patients.
    Bartkó G; Herczeg I; Zádor G
    Acta Psychiatr Scand; 1988 Jan; 77(1):74-6. PubMed ID: 2894746
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Three years' maintenance neuroleptic treatment in schizophrenia--before and beyond.
    Dencker SJ; Frankenberg K; Lepp M; Lindberg D; Malm U
    Acta Psychiatr Scand; 1978 Feb; 57(2):103-14. PubMed ID: 24981
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment.
    Watt DC; Katz K; Shepherd M
    Psychol Med; 1983 Aug; 13(3):663-70. PubMed ID: 6353463
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative study of four evaluation criteria in a clinical trial with schizophrenic patients.
    Fombonne E; Peron-Magnan P; Fuhrer R; Simon P
    Neuropsychobiology; 1986; 16(4):186-92. PubMed ID: 2886952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.